J
301130
vs
NOVN
J
301130
NOVN
Over the past 12 months, Jilin Province Xidian Pharmaceutical Sci-Tech Development Co Ltd has underperformed NOVN, delivering a return of +15% compared to the NOVN's +29% growth.
This Feature is Available on
Paid Plans
Paid Plans
This Feature is Available on Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
14-day money-back guarantee
Smart Verdict
AI-Powered
Not Sure Which Stock Wins?
Let AI Decide.
Let AI Decide.
301130
NOVN
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Summarizing...
We need a little more time to summarize the results
Valuation Comparison
J
Intrinsic Value
15.73
CNY
Overvaluation 49%
NOVN
Intrinsic Value
107.36
CHF
Overvaluation 8%
| Company | Last Price | Intrinsic Value | DCF Value | Multiples-Based Value | Wall St Target | ||
|---|---|---|---|---|---|---|---|
|
J
|
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co Ltd
SZSE:301130
|
30.74
CNY
|
|||||
|
Novartis AG
SIX:NOVN
|
117.32
CHF
|
|||||
No Stocks Selected
Compare the stock's valuation with its competitors.
Valuation Scenario:
Growth Comparison
Growth Over Time
301130, NOVN
301130, NOVN
Revenue
www.alphaspread.com
No Stocks Selected
Compare company's financials with its competitors.
| Company | LTM | Historical Growth | Growth Streak | % Positive Years | Max Drawdown | Volatility | Forecasted Growth | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3 Years | 5 Years | 10 Years | 1 Year | 3 Years | ||||||||
|
J
|
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co Ltd
Revenue
|
|||||||||||
|
|
Novartis AG
Revenue
|
|||||||||||
All metrics are calculated based on data from the last 10 years.
No Stocks Selected
Compare company's financials with its competitors.
Profitability Comparison
Free Cash Flow
301130, NOVN
301130, NOVN
Free Cash Flow
www.alphaspread.com
No Stocks Selected
Compare company's free cash flow with its competitors.
| Company | LTM | Average | Historical Growth | FCF Margin | Conversion | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| 3 Years | 5 Years | 3 Years | 5 Years | 10 Years | ||||||
|
J
|
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co Ltd
SZSE:301130
|
|||||||||
|
|
Novartis AG
SIX:NOVN
|
|||||||||
No Stocks Selected
Compare company's free cash flow with its competitors.
Gross Margin
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co Ltd
73.9%
NOVN
75.8%
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
J
|
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co Ltd | ||||
|
|
Novartis AG | ||||
Operating Margin
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co Ltd
15.1%
NOVN
33.2%
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
J
|
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co Ltd | ||||
|
|
Novartis AG | ||||
Net Margin
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co Ltd
15.6%
NOVN
24.8%
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
J
|
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co Ltd | ||||
|
|
Novartis AG | ||||
FCF Margin
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co Ltd
-6.2%
NOVN
27.1%
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
J
|
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co Ltd | ||||
|
|
Novartis AG | ||||
ROE
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co Ltd
4.3%
NOVN
31%
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
J
|
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co Ltd | ||||
|
|
Novartis AG | ||||
ROA
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co Ltd
3.9%
NOVN
13.1%
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
J
|
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co Ltd | ||||
|
|
Novartis AG | ||||
ROIC
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co Ltd
4.8%
NOVN
17.8%
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
J
|
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co Ltd | ||||
|
|
Novartis AG | ||||
ROCE
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co Ltd
4%
NOVN
23.8%
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
J
|
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co Ltd | ||||
|
|
Novartis AG | ||||
Solvency Comparison
J
Jilin Province Xidian Pharmaceut...
Equity Waterfall
Assets
Liabilities
Equity
No Stocks Selected
Compare company's equity waterfall with its competitors.
Balance Sheet Comparison
Stocks Performance
Stocks Performance
301130, NOVN
301130, NOVN
Performance Gap
301130, NOVN
301130, NOVN
Performance By Year
301130, NOVN
301130, NOVN
Loading
No Stocks Selected
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Not Sure Which Stock Wins?
Let AI Decide
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Compare 301130 to other stocks
LLY
Eli Lilly and Co
Cheaper
vs Jilin Province Xidian Pharmace...
JNJ
Johnson & Johnson
Cheaper
vs Jilin Province Xidian Pharmace...
ROG
Roche Holding AG
Cheaper
vs Jilin Province Xidian Pharmace...
AZN
AstraZeneca PLC
More expensive
vs Jilin Province Xidian Pharmace...
Select Stock to Compare
| US |
|
Eli Lilly and Co
NYSE:LLY
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Loading...
Unlock Full Access to Alpha Spread
Create Free Account
